967 studies found for:    "Macular degeneration"
Show Display Options
Rank Status Study
21 Completed Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Other: Proton beam irradiation and ranibizumab
22 Recruiting VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Interventions: Drug: Ranibizumab;   Drug: Bevacizumab;   Other: No treatment
23 Completed
Has Results
Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: Macugen
24 Unknown  Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Interventions: Drug: ORA102 and Avastin;   Drug: Avastin
25 Completed Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: Palomid 529
26 Unknown  Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System
Conditions: Macular Degeneration;   Choroidal Neovascularization
Intervention: Device: Ocular Brachytherapy
27 Completed A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: rhuFab V2 (ranibizumab)
28 Completed A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: rhuFab V2 (ranibizumab)
29 Recruiting OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
Condition: Wet Macular Degeneration
Interventions: Drug: Ranibizumab;   Drug: OZURDEX
30 Terminated 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: pazopanib eye drops
31 Completed A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: Pazopanib
32 Unknown  Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab
Condition: Wet Macular Degeneration
Interventions: Drug: Ranibizumab;   Drug: Triamcinolone Acetonide
33 Completed
Has Results
Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
34 Active, not recruiting Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
Conditions: Macular Degeneration;   Age-Related Maculopathies;   Age-Related Maculopathy;   Maculopathies, Age-Related;   Maculopathy, Age-Related;   Retinal Degeneration;   Retinal Neovascularization;   Gene Therapy;   Therapy, Gene;   Eye Diseases
Intervention: Biological: AAV2-sFLT01
35 Completed Identification and Treatment of Feeder Vessels in Macular Degeneration
Condition: Macular Degeneration
Interventions: Procedure: Angiography;   Procedure: Laser Treatment
36 Completed Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: AdGVPEDF.11D
37 Completed
Has Results
A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
Condition: Age-related Macular Degeneration
Intervention: Drug: Ranibizumab
38 Recruiting Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
Condition: Macular Degeneration
Intervention:
39 Completed Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
Condition: Wet Macular Degeneration
Interventions: Drug: Ketorolac + Ranibizumab;   Drug: Ranibizumab
40 Completed Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Interventions: Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL;   Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL;   Other: Anecortave Acetate Vehicle

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years